Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
Jinzi WU
Jinzi WU
Positions:

Founder, Chairman & CEO

Company:

Ascletis Pharma Inc.

Dr. Jinzi J. Wu is Founder, Chairman and CEO of Ascletis which was founded in April 2013. Ascletis is an innovative R&D driven biotech with two commercial products. Led by Dr. Wu, Ascletis (1672.HK) became the first pre-revenue biotech listed on the Hong Kong Stock Exchange in August 2018 and raised US$400M. Under his leadership, Ascletis has developed a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Led by Dr. Wu, Ganovo® (Danoprevir), Ascletis’ first direct-acting antiviral agent (DAA) for hepatitis C, was successfully launched in June 2018 and is now commercialized by Ascletis’ 180+ member commercial team. Dr. Wu and his team filed NDA in August 2018 for Ravidasvir, Ascletis’ second DAA for hepatitis C with best-in-class characteristics. Under his leadership, Ascletis has built an innovative R&D pipeline focusing on viral, cancer and fatty liver diseases and consisting of antibody-based immunotherapy, first/best-in-class small molecules and siRNA at various clinical development stages.

 

Dr. Wu has more than 20-year experience covering R&D, GMP manufacturing and commercialization in Big Pharma and biotech. Prior to founding Ascletis, he was Vice President at GSK R&D in USA. He also held various R&D positions from Sr. Scientist to Vice President at Novartis, Immunex/Amgen and Ambrilia in USA and Canada. Dr Wu obtained his PhD in Cancer Biology from University of Arizona.